KMC Speciality

how big is KMC Speciality?

As of Jun 06, KMC Speciality Hospitals (India) Ltd has a market capitalization of 1,102.00 Cr, with recent net sales of 231.59 Cr and a net profit of 21.42 Cr for the latest four quarters.

Market Cap: <BR>As of Jun 06, KMC Speciality Hospitals (India) Ltd has a market capitalization of 1,102.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest 4 quarters, KMC Speciality reported Net Sales of 231.59 Cr and a Net Profit of 21.42 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: <BR>The Standalone balance sheet for the latest annual period ending in Mar'24 shows Shareholder's Funds of 143.58 Cr and Total Assets of 263.72 Cr.

Who are in the management team of KMC Speciality?

As of March 2023, the management team of KMC Speciality includes S Chandrakumar (Executive Chairman), Selvaraj Manivannan (Managing Director), and several non-executive directors, ensuring a diverse governance structure. Other key members include Sushma K (Company Secretary) and S Vijayabaskaran (Non-Executive Director).

As of March 2023, the management team of KMC Speciality includes the following individuals:<BR><BR>1. S Chandrakumar - Executive Chairman & Whole Time Director<BR>2. Selvaraj Manivannan - Managing Director<BR>3. A Krishnamoorthy - Non-Executive & Independent Director<BR>4. S Chenthilkumar - Non-Executive & Independent Director<BR>5. N Bala Baskar - Non-Executive & Independent Director<BR>6. N Jeyanthei - Non-Executive & Independent Director<BR>7. T Senthil Kumar - Non-Executive & Non-Independent Director<BR>8. Sushma K - Company Secretary & Compliance Officer<BR>9. S Vijayabaskaran - Non-Executive Director<BR><BR>This team comprises a mix of executive and non-executive members, ensuring a diverse governance structure.

What does KMC Speciality do?

KMC Speciality Hospitals (India) Ltd is a small-cap company in the hospital industry, reporting net sales of 61 Cr and a net profit of 5 Cr for March 2025. The company has a market cap of Rs 1,090 Cr and key metrics include a P/E ratio of 51.00 and a debt-equity ratio of 0.49.

Overview:<BR>KMC Speciality Hospitals (India) Ltd operates in the hospital industry and is categorized as a small-cap company.<BR><BR>History:<BR>The company was originally incorporated as 'Advanced Medical Care Private Limited' in 1982, converted to a Public Limited Company in 1988, and underwent name changes to 'Seahorse Hospitals Limited' in 1995 and to its current name in 2008. The latest quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 61 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 5 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 1,090 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 51.00<BR>- Industry P/E: 54<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 0.49<BR>- Return on Equity: 13.03%<BR>- Price to Book: 6.68<BR><BR>Contact Details:<BR>Address: 6 Royal Road, Cantonment Trichy Tamil Nadu : 620001 <BR>Tel: 91-431-4077777 <BR>Email: cs.kmcshil@kauveryhospital.com <BR>Website: http://www.kmcspecialityhospital.in

Has KMC Speciality declared dividend?

No Dividend History Available

Who are the peers of the KMC Speciality?

KMC Speciality's peers include Max Healthcare, Apollo Hospitals, Fortis Health, Narayana Hrudaya, Global Health, Asarfi Hospital, Aashka Hospitals, Chandan Healthcare, and Aprameya Enginee. KMC Speciality has average management risk, below average growth, and an excellent capital structure, but its 1-year return is the lowest among peers at -17.65%.

Peers: The peers of KMC Speciality are Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, Asarfi Hospital, Aashka Hospitals, Chandan Healthca, and Aprameya Enginee.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Narayana Hrudaya, Global Health, and Asarfi Hospital, while Good management risk is found at Apollo Hospitals, Fortis Health., and Chandan Healthca. Average management risk is associated with KMC Speciality and Aprameya Enginee, while Below Average management risk is noted at Aashka Hospitals. In terms of Growth, Excellent growth is seen at Max Healthcare, Apollo Hospitals, Chandan Healthca, and Aprameya Enginee, while Good growth is noted at Fortis Health. and Narayana Hrudaya. KMC Speciality and Asarfi Hospital exhibit Below Average growth, while Aashka Hospitals shows Below Average growth. Excellent capital structure is found at Max Healthcare, Global Health, and KMC Speciality, while Good capital structure is noted at Fortis Health., Narayana Hrudaya, Asarfi Hospital, and Chandan Healthca. Average capital structure is observed at Apollo Hospitals and Aprameya Enginee, while Below Average capital structure is seen at Aashka Hospitals.<BR><BR>Return Snapshot: Asarfi Hospital has the highest 1-year return at 110.53%, while KMC Speciality has the lowest at -17.65%. KMC Speciality's 1-year return is significantly lower than all its peers. Additionally, Global Health and KMC Speciality have negative six-month returns.

Who are the top shareholders of the KMC Speciality?

The top shareholder of KMC Speciality is Sri Kauvery Medical Care (India) Limited, holding 75%. D Chitra is the largest individual investor with 1.36%, while individual investors collectively own 22.03% of the shares.

The top shareholders of KMC Speciality are primarily the promoters, with Sri Kauvery Medical Care (India) Limited holding the largest stake at 75%. In terms of public shareholders, D Chitra is the highest individual investor with a holding of 1.36%. Additionally, individual investors collectively hold 22.03% of the shares. There are also four mutual fund schemes and one foreign institutional investor (FII) involved, but their holdings are minimal.

How has been the historical performance of KMC Speciality?

KMC Speciality has shown steady growth in net sales and total operating income, reaching 231.60 Cr in March 2025, but faced declines in profit metrics and increased liabilities, indicating potential profitability challenges. Cash flow from operations improved, contributing to a stronger cash position despite negative investing cash flow.

Answer:<BR>The historical performance of KMC Speciality shows a steady growth in net sales, reaching 231.60 Cr in March 2025, up from 177.18 Cr in March 2024 and 155.76 Cr in March 2023. Total operating income has followed a similar upward trend, increasing to 231.60 Cr in March 2025 from 177.18 Cr in the previous year. The company's total expenditure, excluding depreciation, also rose to 174.71 Cr in March 2025, compared to 129.79 Cr in March 2024. Operating profit, excluding other income, improved to 56.89 Cr in March 2025, while profit before tax decreased to 31.60 Cr from 40.56 Cr in March 2024. Profit after tax also saw a decline to 21.43 Cr in March 2025 from 30.38 Cr in March 2024. The earnings per share (EPS) decreased to 1.31 in March 2025 from 1.86 in March 2024. <BR><BR>In terms of assets and liabilities, total assets increased to 286.00 Cr in March 2025 from 263.72 Cr in March 2024, while total liabilities also rose to 286.00 Cr from 263.72 Cr. The company's long-term borrowings increased to 72.33 Cr in March 2025, up from 63.85 Cr in March 2024. Cash flow from operating activities improved to 57.00 Cr in March 2025, compared to 38.00 Cr in March 2024, while cash flow from investing activities showed a negative trend at -50.00 Cr in March 2025. The closing cash and cash equivalents increased to 9.00 Cr in March 2025 from 4.00 Cr in March 2024, indicating a positive cash position despite the fluctuations in profit metrics.<BR><BR>Breakdown:<BR>KMC Speciality has demonstrated consistent growth in net sales, which rose from 102.64 Cr in March 2021 to 231.60 Cr in March 2025. This growth is reflected in the total operating income, which also increased significantly over the years. However, the total expenditure has risen in tandem, leading to an operating profit of 56.89 Cr in March 2025, a notable increase from previous years. Despite this, profit before tax and profit after tax saw declines in March 2025 compared to the previous year, indicating potential challenges in maintaining profitability. The company's total assets and liabilities have both increased, with long-term borrowings rising significantly, suggesting increased leverage. Cash flow from operating activities has improved, contributing to a stronger cash position, even as cash flow from investing activities remains negative. Overall, while KMC Speciality has shown growth in sales and operating income, profitability metrics and rising liabilities warrant close attention.

Is KMC Speciality overvalued or undervalued?

As of November 13, 2025, KMC Speciality is considered undervalued with a PE Ratio of 41.88 and an attractive valuation compared to peers like Apollo Hospitals and Max Healthcare, while also outperforming the Sensex with a 1-week return of 12.88%.

As of 13 November 2025, KMC Speciality has moved from a fair to an attractive valuation grade. The company is currently considered undervalued, especially when compared to its peers in the hospital industry. Key ratios include a PE Ratio of 41.88, an EV to EBITDA of 19.70, and a ROE of 18.51%. <BR><BR>In comparison to peers, Apollo Hospitals has a significantly higher PE Ratio of 64.07, while Max Healthcare is even more expensive at 88.67. This suggests that KMC Speciality offers a more favorable valuation relative to its competitors. Additionally, KMC's recent stock performance has outpaced the Sensex, with a 1-week return of 12.88% compared to the Sensex's 1.40%, reinforcing the attractiveness of its current valuation.

Is KMC Speciality technically bullish or bearish?

As of November 21, 2025, the trend is mildly bullish due to daily moving averages, but mixed signals from weekly and monthly indicators suggest underlying weaknesses.

As of 21 November 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven primarily by the daily moving averages indicating bullish momentum. However, the weekly MACD and KST are bullish, while the monthly MACD and KST are bearish, suggesting mixed signals across different time frames. The weekly RSI is bearish, which adds to the cautious outlook. Overall, the indicators reflect a mildly bullish sentiment, but with some underlying weaknesses, particularly in the longer-term monthly data.

When is the next results date for KMC Speciality Hospitals (India) Ltd?

The next results date for KMC Speciality Hospitals (India) Ltd is 11 February 2026.

The next results date for KMC Speciality Hospitals (India) Ltd is scheduled for 11 February 2026.

Are KMC Speciality Hospitals (India) Ltd latest results good or bad?

KMC Speciality Hospitals (India) Ltd reported strong Q3 FY26 results, with a net profit of ₹13.73 crore, up 26.67% quarter-on-quarter and 82.83% year-on-year, alongside a revenue increase to ₹82.06 crore. Overall, the results indicate a positive performance and strong market confidence in the company's growth.

KMC Speciality Hospitals (India) Ltd has reported strong results for Q3 FY26, indicating a positive performance. The company achieved a net profit of ₹13.73 crore, which reflects a significant increase of 26.67% quarter-on-quarter and an impressive 82.83% year-on-year growth. Revenue also saw a healthy rise, reaching ₹82.06 crore, up 9.56% from the previous quarter and 33.74% compared to the same quarter last year.<BR><BR>Additionally, the operating margin improved to 30.17%, marking a substantial increase of 235 basis points from the previous quarter and 408 basis points year-on-year. The profit after tax (PAT) margin also expanded to 16.73%, the highest in the company's recent history.<BR><BR>Overall, these results demonstrate a remarkable turnaround for KMC Speciality, showcasing strong operational momentum and improved efficiency. The stock has responded positively, gaining 11.83% over the past week, which reflects market confidence in the company's growth trajectory. Thus, the latest results can be considered very good for KMC Speciality Hospitals.

Which are the latest news on KMC Speciality?

Should I buy, sell or hold KMC Speciality Hospitals (India) Ltd?

Why is KMC Speciality Hospitals (India) Ltd falling/rising?

As of 08-May, KMC Speciality Hospitals (India) Ltd's stock price has risen to Rs. 95.47, reflecting a 6.85% increase, supported by reaching a new 52-week high and significant gains over recent periods, outperforming its sector and the broader market. Increased investor participation and trading above key moving averages further indicate strong market confidence.

As of 08-May, KMC Speciality Hospitals (India) Ltd is experiencing a rise in its stock price, currently at Rs. 95.47, which reflects an increase of Rs. 6.12 or 6.85%. This upward movement is supported by several key factors. <BR><BR>Firstly, the stock has reached a new 52-week high of Rs. 96 today, indicating strong performance. Over the past three days, the stock has gained a total of 11.53%, showcasing a consistent upward trend. Additionally, it has outperformed its sector by 5.05% today, further highlighting its strength in the market.<BR><BR>The stock's performance over various periods also illustrates its positive trajectory. Year-to-date, it has risen by 26.10%, while over the past year, it has increased by 50.49%. Comparatively, the benchmark Sensex has shown a decline of 9.26% year-to-date and a decrease of 3.74% over the past year, indicating that KMC Speciality Hospitals is significantly outperforming the broader market.<BR><BR>Investor participation has also increased, with a delivery volume of 52.74k on 07 May, which is up by 75.28% compared to the five-day average. This suggests growing interest and confidence among investors. Furthermore, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is typically a bullish signal.<BR><BR>Overall, the combination of reaching a new high, strong recent gains, outperformance against the sector, and increased investor participation are all contributing to the rise in KMC Speciality Hospitals' stock price.